SM-1 Research Compound Vial
20mg Multiple Dose Vial
$45.00$25.00
Here are the key potential benefits, based on clinical evidence:
Substantial and Sustained Weight Loss
In people with overweight or obesity (without diabetes), once-weekly subcutaneous semaglutide (typically 2.4 mg) leads to average weight reductions of ~12-17% over 68 weeks, with some trials showing sustained ~10% loss over 4 years.
Many achieve clinically meaningful thresholds: ~85-90% lose ≥5%, ~70-80% lose ≥10%, and ~30-50% lose ≥15-20%.
Higher doses (e.g., up to 7.2 mg in recent 2025 trials) can increase this to ~13-19% loss.
Benefits include reduced waist circumference (~7-13 cm), BMI, and visceral fat, while often preserving lean muscle mass relatively better than diet alone.
Improved Glycemic Control (Especially in Type 2 Diabetes)
Significantly lowers HbA1c (by ~1-2 percentage points on average) and fasting blood glucose.
Promotes better long-term blood sugar management, often reducing the need for other diabetes medications.
Cardiovascular Protection
Reduces major adverse cardiovascular events (MACE — e.g., heart attack, stroke, cardiovascular death) by ~20% in people with overweight/obesity and preexisting heart disease (SELECT trial), even beyond what weight loss alone explains.
Benefits seen in both those with and without type 2 diabetes, including lower blood pressure, improved lipid profiles (e.g., reduced LDL/total cholesterol, triglycerides), and decreased inflammation (e.g., lower C-reactive protein).
Kidney Protection
Slows progression of chronic kidney disease (CKD), reduces albuminuria (protein in urine), and preserves kidney function (e.g., ~24% lower risk of major kidney events in FLOW trial for type 2 diabetes patients with CKD).
Label expansions (as of 2025) reflect these renoprotective effects.
Liver Health (e.g., NAFLD/MASLD/MASH)
Reduces liver fat accumulation, improves steatosis, inflammation, and fibrosis markers in non-alcoholic fatty liver disease (often tied to obesity and metabolic issues).
Emerging approvals and data position it as a key option for metabolic-associated steatotic liver disease.
Other Benefits
Improves physical functioning, quality of life, and cardiometabolic risk factors (e.g., better endothelial function, reduced arterial stiffness).
Potential reductions in heart failure hospitalizations/symptoms and broader anti-inflammatory effects.
Some evidence for benefits in related conditions (e.g., PCOS, peripheral artery disease symptoms, or even exploratory areas like inflammation in specific populations).
These effects often occur alongside lifestyle changes (diet/exercise) and stem from semaglutide's actions on appetite suppression, delayed gastric emptying, insulin/glucagon regulation, and direct organ-protective mechanisms.
Note: Benefits vary by individual factors (dose, duration, adherence, baseline health). While highly effective for many, it's not suitable for everyone, and potential side effects (mostly gastrointestinal like nausea) should be discussed with a healthcare provider. Ongoing research continues to expand its applications as of 2026.
